TriSalus Life Sciences Inc

Insider buying surges at TriSalus Life Sciences after a $40 M offer—executives buy at $4.10, boosting confidence in its liver‑pancreas immunotherapy platform.

TriSalus insider move: Co‑founder Michael Stansky exercises zero‑price stock option, hinting at optimism amid a modestly volatile, pre‑commercial biotech platform targeting liver and pancreas tumors—watch partnerships, trials and capital raises.